Loss of vancomycin bactericidal activity against accessory gene regulator (agr) dysfunctional Staphylococcus aureus under conditions of high bacterial density

Diagnostic Microbiology and Infectious Disease

Volumn 64, Issue 2, 2009, Pages 220-224

  Tsuji, Brian T ^a,e   Harigaya, Yoriko ^a   Lesse, Alan J ^b,c   Sakoulas, George ^d,f   Mylotte, Joseph M ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b Sch of Med and Biomedical Sciences   (United States)

^c VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f SHARP HEALTHCARE   (United States)

Author keywords

Accessory gene regulator; Bloodstream infection; Staphylococcus aureus; Vancomycin

Indexed keywords

ACCESSORY GENE REGULATOR PROTEIN; BACTERIAL PROTEIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL GENETICS; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BACTERIUM MUTANT; CELL DENSITY; CONTROLLED STUDY; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL PROTEINS; COLONY COUNT, MICROBIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL VIABILITY; MUTATION; STAPHYLOCOCCAL INFECTIONS; TIME FACTORS; TRANS-ACTIVATORS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 67349128581     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.01.028     Document Type: Article

References (18)

1. Hidayat L.K., Hsu D.I., Quist R., Shriner K.A., and Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 166 (2006) 2138-2144
2. Hiramatsu K., Aritaka N., Hanaki H., Kawasaki S., Hosoda Y., Hori S., Fukuchi Y., and Kobayashi I. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350 (1997) 1670-1673
3. Howden B.P., Johnson P.D., Ward P.B., Stinear T.P., and Davies J.K. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 50 (2006) 3039-3047
4. Infectious Diseases Society of America/American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005) 388-416
5. Lamer C., de Beco V., Soler P., Calvat S., Fagon J.Y., Dombret M.C., Farinotti R., Chastre J., and Gibert C. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 37 (1993) 281-286
6. Lamp K.C., Rybak M.J., Bailey E.M., and Kaatz G.W. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob Agents Chemother 36 (1992) 2709-2714
7. LaPlante K.L., and Rybak M.J. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 48 (2004) 4665-4672
8. Moise P.A., Sakoulas G., Forrest A., and Schentag J.J. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 51 (2007) 2582-2586
9. Novick R.P. Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol Microbiol 48 (2003) 1429-1449
10. Sakoulas G., Eliopoulos G.M., Moellering Jr. R.C., Wennersten C., Venkataraman L., Novick R.P., and Gold H.S. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 46 (2002) 1492-1502
11. Sakoulas G., Moise-Broder P.A., Schentag J., Forrest A., Moellering Jr. R.C., and Eliopoulos G.M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42 (2004) 2398-2402
12. Sakoulas G., Moellering Jr. R.C., and Eliopoulos G.M. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis 42 Suppl 1 (2006) S40-S50
13. Sakoulas G., Gold H.S., Cohen R.A., Venkataraman L., Moellering R.C., and Eliopoulos G.M. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 57 (2006) 699-704
14. Smith P.F., Tsuji B., Booker B.M., Forrest A., Bajic S., Kelchlin P., Bhavnani S.M., Jones R.N., and Ambrose P.G. Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic model. Diagn Microbiol Infect Dis 56 (2006) 379-386
15. Tsuji B.T., Rybak M.J., Lau K.L., and Sakoulas G. Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother 51 (2007) 1089-1091
16. Tsuji B.T., von Eiff C., Kelchlin P.A., Forrest A., and Smith P.F. Attenuated vancomycin bactericidal activity against Staphylococcus aureus hemB mutants expressing the small-colony-variant phenotype. Antimicrob Agents Chemother 52 (2008) 1533-1537
17. Vuong C., Saenz H.L., Gotz F., and Otto M. Impact of the agr quorum-sensing system on adherence to polystyrene in Staphylococcus aureus. J Infect Dis 182 (2000) 1688-1693
18. Yarwood J.M., and Schlievert P.M. Quorum sensing in Staphylococcus infections. J Clin Invest 112 (2003) 1620-1625